Global Homozygous Familial Hypercholesterolemia Treatment Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
As the global economy mends, the 2021 growth of Homozygous Familial Hypercholesterolemia Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Homozygous Familial Hypercholesterolemia Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Homozygous Familial Hypercholesterolemia Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Homozygous Familial Hypercholesterolemia Treatment market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Homozygous Familial Hypercholesterolemia Treatment market, reaching US$ million by the year 2028. As for the Europe Homozygous Familial Hypercholesterolemia Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Homozygous Familial Hypercholesterolemia Treatment players cover CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, and LipimetiX Development Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Homozygous Familial Hypercholesterolemia Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
As the global economy mends, the 2021 growth of Homozygous Familial Hypercholesterolemia Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Homozygous Familial Hypercholesterolemia Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Homozygous Familial Hypercholesterolemia Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Homozygous Familial Hypercholesterolemia Treatment market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Homozygous Familial Hypercholesterolemia Treatment market, reaching US$ million by the year 2028. As for the Europe Homozygous Familial Hypercholesterolemia Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Homozygous Familial Hypercholesterolemia Treatment players cover CymaBay Therapeutics Inc, Daewoong Co Ltd, Gemphire Therapeutics Inc, and LipimetiX Development Inc, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Homozygous Familial Hypercholesterolemia Treatment market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
- AEM-2802
- AEM-2814
- Alirocumab
- Evinacumab
- Others
- Clinic
- Hospital
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- CymaBay Therapeutics Inc
- Daewoong Co Ltd
- Gemphire Therapeutics Inc
- LipimetiX Development Inc
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- The Medicines Company
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Homozygous Familial Hypercholesterolemia Treatment by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Homozygous Familial Hypercholesterolemia Treatment by Country/Region, 2017, 2022 & 2028
2.2 Homozygous Familial Hypercholesterolemia Treatment Segment by Type
2.2.1 AEM-2802
2.2.2 AEM-2814
2.2.3 Alirocumab
2.2.4 Evinacumab
2.2.5 Others
2.3 Homozygous Familial Hypercholesterolemia Treatment Sales by Type
2.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
2.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue and Market Share by Type (2017-2022)
2.3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Type (2017-2022)
2.4 Homozygous Familial Hypercholesterolemia Treatment Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Homozygous Familial Hypercholesterolemia Treatment Sales by Application
2.5.1 Global Homozygous Familial Hypercholesterolemia Treatment Sale Market Share by Application (2017-2022)
2.5.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue and Market Share by Application (2017-2022)
2.5.3 Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Application (2017-2022)
3 GLOBAL HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT BY COMPANY
3.1 Global Homozygous Familial Hypercholesterolemia Treatment Breakdown Data by Company
3.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales by Company (2020-2022)
3.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Company (2020-2022)
3.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue by Company (2020-2022)
3.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Company (2020-2022)
3.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Company (2020-2022)
3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Company
3.4 Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Product Location Distribution
3.4.2 Players Homozygous Familial Hypercholesterolemia Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Homozygous Familial Hypercholesterolemia Treatment Market Size by Geographic Region (2017-2022)
4.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue by Geographic Region
4.2 World Historic Homozygous Familial Hypercholesterolemia Treatment Market Size by Country/Region (2017-2022)
4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales by Country/Region (2017-2022)
4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue by Country/Region
4.3 Americas Homozygous Familial Hypercholesterolemia Treatment Sales Growth
4.4 APAC Homozygous Familial Hypercholesterolemia Treatment Sales Growth
4.5 Europe Homozygous Familial Hypercholesterolemia Treatment Sales Growth
4.6 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Growth
5 AMERICAS
5.1 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Country
5.1.1 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022)
5.1.2 Americas Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022)
5.2 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Type
5.3 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Region
6.1.1 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022)
6.1.2 APAC Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022)
6.2 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Type
6.3 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Homozygous Familial Hypercholesterolemia Treatment by Country
7.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022)
7.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022)
7.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type
7.3 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment by Country
8.1.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022)
8.1.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022)
8.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type
8.3 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Homozygous Familial Hypercholesterolemia Treatment
10.3 Manufacturing Process Analysis of Homozygous Familial Hypercholesterolemia Treatment
10.4 Industry Chain Structure of Homozygous Familial Hypercholesterolemia Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
11.3 Homozygous Familial Hypercholesterolemia Treatment Customer
12 WORLD FORECAST REVIEW FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT BY GEOGRAPHIC REGION
12.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Region
12.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Forecast by Region (2023-2028)
12.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Homozygous Familial Hypercholesterolemia Treatment Forecast by Type
12.7 Global Homozygous Familial Hypercholesterolemia Treatment Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 CymaBay Therapeutics Inc
13.1.1 CymaBay Therapeutics Inc Company Information
13.1.2 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.1.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 CymaBay Therapeutics Inc Main Business Overview
13.1.5 CymaBay Therapeutics Inc Latest Developments
13.2 Daewoong Co Ltd
13.2.1 Daewoong Co Ltd Company Information
13.2.2 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.2.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Daewoong Co Ltd Main Business Overview
13.2.5 Daewoong Co Ltd Latest Developments
13.3 Gemphire Therapeutics Inc
13.3.1 Gemphire Therapeutics Inc Company Information
13.3.2 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.3.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Gemphire Therapeutics Inc Main Business Overview
13.3.5 Gemphire Therapeutics Inc Latest Developments
13.4 LipimetiX Development Inc
13.4.1 LipimetiX Development Inc Company Information
13.4.2 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 LipimetiX Development Inc Main Business Overview
13.4.5 LipimetiX Development Inc Latest Developments
13.5 Regeneron Pharmaceuticals Inc
13.5.1 Regeneron Pharmaceuticals Inc Company Information
13.5.2 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.5.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.5.5 Regeneron Pharmaceuticals Inc Latest Developments
13.6 RegenxBio Inc
13.6.1 RegenxBio Inc Company Information
13.6.2 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.6.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 RegenxBio Inc Main Business Overview
13.6.5 RegenxBio Inc Latest Developments
13.7 The Medicines Company
13.7.1 The Medicines Company Company Information
13.7.2 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.7.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 The Medicines Company Main Business Overview
13.7.5 The Medicines Company Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Homozygous Familial Hypercholesterolemia Treatment by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Homozygous Familial Hypercholesterolemia Treatment by Country/Region, 2017, 2022 & 2028
2.2 Homozygous Familial Hypercholesterolemia Treatment Segment by Type
2.2.1 AEM-2802
2.2.2 AEM-2814
2.2.3 Alirocumab
2.2.4 Evinacumab
2.2.5 Others
2.3 Homozygous Familial Hypercholesterolemia Treatment Sales by Type
2.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
2.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue and Market Share by Type (2017-2022)
2.3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Type (2017-2022)
2.4 Homozygous Familial Hypercholesterolemia Treatment Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Homozygous Familial Hypercholesterolemia Treatment Sales by Application
2.5.1 Global Homozygous Familial Hypercholesterolemia Treatment Sale Market Share by Application (2017-2022)
2.5.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue and Market Share by Application (2017-2022)
2.5.3 Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Application (2017-2022)
3 GLOBAL HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT BY COMPANY
3.1 Global Homozygous Familial Hypercholesterolemia Treatment Breakdown Data by Company
3.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales by Company (2020-2022)
3.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Company (2020-2022)
3.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue by Company (2020-2022)
3.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Company (2020-2022)
3.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Company (2020-2022)
3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Company
3.4 Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Product Location Distribution
3.4.2 Players Homozygous Familial Hypercholesterolemia Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT BY GEOGRAPHIC REGION
4.1 World Historic Homozygous Familial Hypercholesterolemia Treatment Market Size by Geographic Region (2017-2022)
4.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue by Geographic Region
4.2 World Historic Homozygous Familial Hypercholesterolemia Treatment Market Size by Country/Region (2017-2022)
4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Annual Sales by Country/Region (2017-2022)
4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue by Country/Region
4.3 Americas Homozygous Familial Hypercholesterolemia Treatment Sales Growth
4.4 APAC Homozygous Familial Hypercholesterolemia Treatment Sales Growth
4.5 Europe Homozygous Familial Hypercholesterolemia Treatment Sales Growth
4.6 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Growth
5 AMERICAS
5.1 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Country
5.1.1 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022)
5.1.2 Americas Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022)
5.2 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Type
5.3 Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Region
6.1.1 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022)
6.1.2 APAC Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022)
6.2 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Type
6.3 APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Homozygous Familial Hypercholesterolemia Treatment by Country
7.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022)
7.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022)
7.2 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type
7.3 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment by Country
8.1.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022)
8.1.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022)
8.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type
8.3 Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Homozygous Familial Hypercholesterolemia Treatment
10.3 Manufacturing Process Analysis of Homozygous Familial Hypercholesterolemia Treatment
10.4 Industry Chain Structure of Homozygous Familial Hypercholesterolemia Treatment
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
11.3 Homozygous Familial Hypercholesterolemia Treatment Customer
12 WORLD FORECAST REVIEW FOR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TREATMENT BY GEOGRAPHIC REGION
12.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Forecast by Region
12.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Forecast by Region (2023-2028)
12.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Homozygous Familial Hypercholesterolemia Treatment Forecast by Type
12.7 Global Homozygous Familial Hypercholesterolemia Treatment Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 CymaBay Therapeutics Inc
13.1.1 CymaBay Therapeutics Inc Company Information
13.1.2 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.1.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 CymaBay Therapeutics Inc Main Business Overview
13.1.5 CymaBay Therapeutics Inc Latest Developments
13.2 Daewoong Co Ltd
13.2.1 Daewoong Co Ltd Company Information
13.2.2 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.2.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Daewoong Co Ltd Main Business Overview
13.2.5 Daewoong Co Ltd Latest Developments
13.3 Gemphire Therapeutics Inc
13.3.1 Gemphire Therapeutics Inc Company Information
13.3.2 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.3.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Gemphire Therapeutics Inc Main Business Overview
13.3.5 Gemphire Therapeutics Inc Latest Developments
13.4 LipimetiX Development Inc
13.4.1 LipimetiX Development Inc Company Information
13.4.2 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 LipimetiX Development Inc Main Business Overview
13.4.5 LipimetiX Development Inc Latest Developments
13.5 Regeneron Pharmaceuticals Inc
13.5.1 Regeneron Pharmaceuticals Inc Company Information
13.5.2 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.5.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Regeneron Pharmaceuticals Inc Main Business Overview
13.5.5 Regeneron Pharmaceuticals Inc Latest Developments
13.6 RegenxBio Inc
13.6.1 RegenxBio Inc Company Information
13.6.2 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.6.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 RegenxBio Inc Main Business Overview
13.6.5 RegenxBio Inc Latest Developments
13.7 The Medicines Company
13.7.1 The Medicines Company Company Information
13.7.2 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Offered
13.7.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 The Medicines Company Main Business Overview
13.7.5 The Medicines Company Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Homozygous Familial Hypercholesterolemia Treatment Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Homozygous Familial Hypercholesterolemia Treatment Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of AEM-2802
Table 4. Major Players of AEM-2814
Table 5. Major Players of Alirocumab
Table 6. Major Players of Evinacumab
Table 7. Major Players of Others
Table 8. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 10. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & ($ million)
Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2022)
Table 12. Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Type (2017-2022) & (USD/Pcs)
Table 13. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022)
Table 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2022)
Table 17. Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Application (2017-2022) & (USD/Pcs)
Table 18. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Company (2020-2022) & (K Pcs)
Table 19. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Company (2020-2022)
Table 20. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Company (2020-2022) ($ Millions)
Table 21. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Company (2020-2022)
Table 22. Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Company (2020-2022) & (USD/Pcs)
Table 23. Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Producing Area Distribution and Sales Area
Table 24. Players Homozygous Familial Hypercholesterolemia Treatment Products Offered
Table 25. Homozygous Familial Hypercholesterolemia Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Geographic Region (2017-2022) & (K Pcs)
Table 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Geographic Region (2017-2022)
Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country/Region (2017-2022) & (K Pcs)
Table 33. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country/Region (2017-2022)
Table 34. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
Table 37. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2017-2022)
Table 38. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2017-2022)
Table 40. Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 41. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 42. Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 43. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 44. APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022) & (K Pcs)
Table 45. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2017-2022)
Table 46. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2017-2022)
Table 48. APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 49. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 50. APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 51. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 52. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
Table 53. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2017-2022)
Table 54. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2017-2022)
Table 56. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 57. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 58. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 59. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
Table 61. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 65. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 67. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of Homozygous Familial Hypercholesterolemia Treatment
Table 69. Key Market Challenges & Risks of Homozygous Familial Hypercholesterolemia Treatment
Table 70. Key Industry Trends of Homozygous Familial Hypercholesterolemia Treatment
Table 71. Homozygous Familial Hypercholesterolemia Treatment Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Homozygous Familial Hypercholesterolemia Treatment Distributors List
Table 74. Homozygous Familial Hypercholesterolemia Treatment Customer List
Table 75. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Region (2023-2028) & (K Pcs)
Table 76. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Forecast by Region
Table 77. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2023-2028) & (K Pcs)
Table 80. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Region (2023-2028) & (K Pcs)
Table 82. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2023-2028) & (K Pcs)
Table 84. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2023-2028) & (K Pcs)
Table 86. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Type (2023-2028) & (K Pcs)
Table 88. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Application (2023-2028) & (K Pcs)
Table 92. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Application (2023-2028)
Table 95. CymaBay Therapeutics Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 96. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 97. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 98. CymaBay Therapeutics Inc Main Business
Table 99. CymaBay Therapeutics Inc Latest Developments
Table 100. Daewoong Co Ltd Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 101. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 102. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 103. Daewoong Co Ltd Main Business
Table 104. Daewoong Co Ltd Latest Developments
Table 105. Gemphire Therapeutics Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 106. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 107. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 108. Gemphire Therapeutics Inc Main Business
Table 109. Gemphire Therapeutics Inc Latest Developments
Table 110. LipimetiX Development Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 111. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 112. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 113. LipimetiX Development Inc Main Business
Table 114. LipimetiX Development Inc Latest Developments
Table 115. Regeneron Pharmaceuticals Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 116. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 117. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 118. Regeneron Pharmaceuticals Inc Main Business
Table 119. Regeneron Pharmaceuticals Inc Latest Developments
Table 120. RegenxBio Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 121. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 122. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 123. RegenxBio Inc Main Business
Table 124. RegenxBio Inc Latest Developments
Table 125. The Medicines Company Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 126. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 127. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 128. The Medicines Company Main Business
Table 129. The Medicines Company Latest Developments
Table 1. Homozygous Familial Hypercholesterolemia Treatment Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Homozygous Familial Hypercholesterolemia Treatment Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of AEM-2802
Table 4. Major Players of AEM-2814
Table 5. Major Players of Alirocumab
Table 6. Major Players of Evinacumab
Table 7. Major Players of Others
Table 8. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 10. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & ($ million)
Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2022)
Table 12. Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Type (2017-2022) & (USD/Pcs)
Table 13. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022)
Table 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2022)
Table 17. Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Application (2017-2022) & (USD/Pcs)
Table 18. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Company (2020-2022) & (K Pcs)
Table 19. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Company (2020-2022)
Table 20. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Company (2020-2022) ($ Millions)
Table 21. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Company (2020-2022)
Table 22. Global Homozygous Familial Hypercholesterolemia Treatment Sale Price by Company (2020-2022) & (USD/Pcs)
Table 23. Key Manufacturers Homozygous Familial Hypercholesterolemia Treatment Producing Area Distribution and Sales Area
Table 24. Players Homozygous Familial Hypercholesterolemia Treatment Products Offered
Table 25. Homozygous Familial Hypercholesterolemia Treatment Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Geographic Region (2017-2022) & (K Pcs)
Table 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Geographic Region (2017-2022)
Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Geographic Region (2017-2022) & ($ millions)
Table 31. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Geographic Region (2017-2022)
Table 32. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Country/Region (2017-2022) & (K Pcs)
Table 33. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country/Region (2017-2022)
Table 34. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Country/Region (2017-2022) & ($ millions)
Table 35. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country/Region (2017-2022)
Table 36. Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
Table 37. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2017-2022)
Table 38. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 39. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2017-2022)
Table 40. Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 41. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 42. Americas Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 43. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 44. APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022) & (K Pcs)
Table 45. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2017-2022)
Table 46. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022) & ($ Millions)
Table 47. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2017-2022)
Table 48. APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 49. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 50. APAC Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 51. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 52. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
Table 53. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2017-2022)
Table 54. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 55. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2017-2022)
Table 56. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 57. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 58. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 59. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 60. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
Table 61. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country (2017-2022)
Table 62. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & ($ Millions)
Table 63. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country (2017-2022)
Table 64. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
Table 65. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2022)
Table 66. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
Table 67. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Table 68. Key Market Drivers & Growth Opportunities of Homozygous Familial Hypercholesterolemia Treatment
Table 69. Key Market Challenges & Risks of Homozygous Familial Hypercholesterolemia Treatment
Table 70. Key Industry Trends of Homozygous Familial Hypercholesterolemia Treatment
Table 71. Homozygous Familial Hypercholesterolemia Treatment Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Homozygous Familial Hypercholesterolemia Treatment Distributors List
Table 74. Homozygous Familial Hypercholesterolemia Treatment Customer List
Table 75. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Region (2023-2028) & (K Pcs)
Table 76. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Forecast by Region
Table 77. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 78. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Region (2023-2028)
Table 79. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2023-2028) & (K Pcs)
Table 80. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 81. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Region (2023-2028) & (K Pcs)
Table 82. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Region (2023-2028) & ($ millions)
Table 83. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2023-2028) & (K Pcs)
Table 84. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Country (2023-2028) & (K Pcs)
Table 86. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Country (2023-2028) & ($ millions)
Table 87. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Type (2023-2028) & (K Pcs)
Table 88. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 90. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Homozygous Familial Hypercholesterolemia Treatment Sales Forecast by Application (2023-2028) & (K Pcs)
Table 92. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 94. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share Forecast by Application (2023-2028)
Table 95. CymaBay Therapeutics Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 96. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 97. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 98. CymaBay Therapeutics Inc Main Business
Table 99. CymaBay Therapeutics Inc Latest Developments
Table 100. Daewoong Co Ltd Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 101. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 102. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 103. Daewoong Co Ltd Main Business
Table 104. Daewoong Co Ltd Latest Developments
Table 105. Gemphire Therapeutics Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 106. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 107. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 108. Gemphire Therapeutics Inc Main Business
Table 109. Gemphire Therapeutics Inc Latest Developments
Table 110. LipimetiX Development Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 111. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 112. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 113. LipimetiX Development Inc Main Business
Table 114. LipimetiX Development Inc Latest Developments
Table 115. Regeneron Pharmaceuticals Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 116. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 117. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 118. Regeneron Pharmaceuticals Inc Main Business
Table 119. Regeneron Pharmaceuticals Inc Latest Developments
Table 120. RegenxBio Inc Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 121. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 122. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 123. RegenxBio Inc Main Business
Table 124. RegenxBio Inc Latest Developments
Table 125. The Medicines Company Basic Information, Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base, Sales Area and Its Competitors
Table 126. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Offered
Table 127. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)
Table 128. The Medicines Company Main Business
Table 129. The Medicines Company Latest Developments
LIST OF FIGURES
Figure 1. Picture of Homozygous Familial Hypercholesterolemia Treatment
Figure 2. Homozygous Familial Hypercholesterolemia Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2017-2028 (K Pcs)
Figure 7. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of AEM-2802
Figure 10. Product Picture of AEM-2814
Figure 11. Product Picture of Alirocumab
Figure 12. Product Picture of Evinacumab
Figure 13. Product Picture of Others
Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type in 2021
Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2022)
Figure 16. Homozygous Familial Hypercholesterolemia Treatment Consumed in Clinic
Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Market: Clinic (2017-2022) & (K Pcs)
Figure 18. Homozygous Familial Hypercholesterolemia Treatment Consumed in Hospital
Figure 19. Global Homozygous Familial Hypercholesterolemia Treatment Market: Hospital (2017-2022) & (K Pcs)
Figure 20. Homozygous Familial Hypercholesterolemia Treatment Consumed in Others
Figure 21. Global Homozygous Familial Hypercholesterolemia Treatment Market: Others (2017-2022) & (K Pcs)
Figure 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Figure 23. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application in 2021
Figure 24. Homozygous Familial Hypercholesterolemia Treatment Revenue Market by Company in 2021 ($ Million)
Figure 25. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Company in 2021
Figure 26. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Geographic Region in 2021
Figure 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2017-2022)
Figure 29. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country/Region in 2021
Figure 30. Americas Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 31. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 32. APAC Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 33. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 34. Europe Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 35. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 37. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 38. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2021
Figure 39. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2021
Figure 40. United States Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region in 2021
Figure 45. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Regions in 2021
Figure 46. China Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 50. India Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2021
Figure 53. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2021
Figure 54. Germany Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 55. France Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2021
Figure 60. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2021
Figure 61. Egypt Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of Homozygous Familial Hypercholesterolemia Treatment in 2021
Figure 67. Manufacturing Process Analysis of Homozygous Familial Hypercholesterolemia Treatment
Figure 68. Industry Chain Structure of Homozygous Familial Hypercholesterolemia Treatment
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Figure 1. Picture of Homozygous Familial Hypercholesterolemia Treatment
Figure 2. Homozygous Familial Hypercholesterolemia Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Homozygous Familial Hypercholesterolemia Treatment Sales Growth Rate 2017-2028 (K Pcs)
Figure 7. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of AEM-2802
Figure 10. Product Picture of AEM-2814
Figure 11. Product Picture of Alirocumab
Figure 12. Product Picture of Evinacumab
Figure 13. Product Picture of Others
Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type in 2021
Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2022)
Figure 16. Homozygous Familial Hypercholesterolemia Treatment Consumed in Clinic
Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Market: Clinic (2017-2022) & (K Pcs)
Figure 18. Homozygous Familial Hypercholesterolemia Treatment Consumed in Hospital
Figure 19. Global Homozygous Familial Hypercholesterolemia Treatment Market: Hospital (2017-2022) & (K Pcs)
Figure 20. Homozygous Familial Hypercholesterolemia Treatment Consumed in Others
Figure 21. Global Homozygous Familial Hypercholesterolemia Treatment Market: Others (2017-2022) & (K Pcs)
Figure 22. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2022)
Figure 23. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application in 2021
Figure 24. Homozygous Familial Hypercholesterolemia Treatment Revenue Market by Company in 2021 ($ Million)
Figure 25. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Company in 2021
Figure 26. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Geographic Region in 2021
Figure 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2017-2022)
Figure 29. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country/Region in 2021
Figure 30. Americas Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 31. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 32. APAC Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 33. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 34. Europe Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 35. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2022 (K Pcs)
Figure 37. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2022 ($ Millions)
Figure 38. Americas Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2021
Figure 39. Americas Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2021
Figure 40. United States Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region in 2021
Figure 45. APAC Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Regions in 2021
Figure 46. China Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 50. India Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2021
Figure 53. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2021
Figure 54. Germany Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 55. France Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Country in 2021
Figure 60. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Country in 2021
Figure 61. Egypt Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country Homozygous Familial Hypercholesterolemia Treatment Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of Homozygous Familial Hypercholesterolemia Treatment in 2021
Figure 67. Manufacturing Process Analysis of Homozygous Familial Hypercholesterolemia Treatment
Figure 68. Industry Chain Structure of Homozygous Familial Hypercholesterolemia Treatment
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
